Adamantiades-Behcet's disease (ABO) is a chronic systemic vasculitis with unknown cause and characterized by recurrent oral and genital aphthous ulcerations, ocular inflammation and skin and joint manifestation (1) . The underlying pathology includes an inflammatory process of arteries and veins (2) (3) . The immune system is involved and activated in the course of the disease. Increased neutrophil functions such as chemotaxis, phagocytosis and excessive production of reactive oxygen species, as well as immunologic alterations, T lymphocyte abnormalities in both subpopulation and function have been correlated to the etiopathogenesis of ABO (4) (5) . Histopathological examination shows cellular infiltration in the majority of Adamantiades-Behcet's lesions, consisting of lymphocytes, plasma cells, monocytes and neutrophils in varying proportions, depending on the stage of the lesions (3, 6) .
Members of the C-C subfamily are monocyte chemotactic proteins (MCP-I ,2,3), macrophage inflammatory proteins (MIP-Ia, l~, 3a, 3~) and other proteins (7) . MCP-I is secreted by monocytes, macrophages and a large number of other cells. It generally induces histamine release from intradermal mast cells, stimulates exocytosis, promotes prostaglandin 02 generation and acts as a chemoattractant for monocytes and T cells of the memory subtype (8) . ABO is an inflammatory disease. Therefore, levels of pro-inflammatory cytokines should form the subject of a cohort study during the course of ABO (9) .
Vascular endothelial growth factor (VEGF) is a potent cytokine that modulates angiogenesis and vasculogenesis by acting as an essential mitogen for vascular endothelial cells. It can be produced by many cell types including macrophages, monocytes, neutrophils and endothelial. VEGF is expressed on the systemic and retinal vascular endothelial cells, the expression being induced by pro-inflammatory cytokines (I 0).
Adenosine deaminase (ADA; EC3.5.4.4.) participates in the degradation of purines by catalysing the conversion of adenosine to inosine and deoxyadenosine to deoxyinosine. Two isoenzymes of total ADA (tADA), ADA 1 and ADA2 have been described (11) (12) . ADA is present in serum and in most tissues, particularly lymphoid tissues. ADA activity is highest in T lymphocytes and macrophages and it has been considered as a nonspecific marker ofT cell activation (13) (14) . The aim of the study was to investigate the markers that indicate the activity and the remission of ABD.
MATERIALS AND METHODS
A 10 year old boy came to the Department of Ophthalmology because of visual deterioration in both eyes. Visual acuity was 0.2 in the right and 0.3 in the left eye. Further ophthalmologic findings were typical of posterior uveitis, including vitreous cells, optic disc oedema, cystoid macular oedema, lesions of the retinal pigment epithelium and peripheral retinal vasculitis. The pediatric physical examination also disclosed aphthous stomatitis and recurrent aphthous genital ulcers.
The diagnosis of Adamantiades-Behcet's disease was made according to the criteria for diagnosis of the International Study Group for AdamantiadesBehcet's disease. It was based on bilateral acute posterior uveitis due to vaso-occlusive vasculitis in association with aphthous stomatitis and recurrent genital ulcers. Since there is no clinically acceptable scoring system and laboratory screening profile to define the severity of ABD, the patient was evaluated by both clinical and laboratory findings. The clinical evaluation, worsening of clinical symptoms at the time of study and having at least three of the major symptoms (oral ulcers, genital ulcers and uveitis), was considered to be characteristic of the active period of the disease. During the inactive period the patient had no symptoms or signs of disease activity. On diagnosis, the laboratory investigation yielded an erythrocyte sedimentation rate (ERS) of75 mm the 1st hand Creactive protein (CRP) 40.3 mg/dl, WBC 10200/mm J with 8200/mm J neutrophils. He was HLA-B5l positive. Corticosteroid therapy was initiated with oral prednisone 60 mg daily. The bilateral uveitis improved markedly.
Unfortunately, the patient discontinued the prescribed therapy 11 months after the first 
diagnosis and initiation of the treatment and, immediately thereafter, he experienced severe bilateral central vaso-oclussive retinitis, with visual deterioration. A new high dose corticosteroid therapy was administered parenterally, followed by oral prednisone and azathioprine. Blood samples from the patient were collected at the time of the initial diagnosis, before the start of the treatment and then every month for 4 months and at relapse. Blood samples were used for evaluated leukocyte counts, ERS, CRP, al antitrypsin, a2 macroglobulin, IL-I/3, IL-6, IL-8, TNF-a, sIL-2R, VEGF, MCP-l, serum tADA activity, ADAI and ADA2. Tables I and II show the results of neutrophil counts, ERS, CRP, al antitrypsin, a2 macroglobulin, IL-l/3, IL-6, IL-8, TNF-a, sIL-2R, VEGF, MCP-l, serum tADA activity, ADAI and ADA2. Blood sample from a healthy volunteer matched in age and sex with the patient, was taken to determine the above parameters (Tables I and II) .
Serum tAD A activity was measured by a spectrophotometer using adenosine as the substrate (Method by Giusti, 15) . The principle of this method is to measure the amount of ammonia released during the conversion of adenosine to inosine, using the Berthelot reaction. The results are expressed as U/L in the serum. One Unit of tADA is defined as the amount of enzyme required to release 1umol of ammonia per minute from adenosine at standard assay conditions. Sera without hemolysis were used, because erythrocytes contain ADA activity and can falsely increase the tADA results for serum.
The activities of ADA2 and tADA in the presence or absence of 0.1 mmol/L EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine, Sigma) were measured, and ADAI activity was calculated by subtracting the activity ofADA2 from that of tADA activity. This method is based on the fact that ADA2 has greater resistance to inhibition by EHNA than does ADA 1. This method is suitable for reliable quantification of tADA isoenzymes and analysis of large numbers of samples in clinical laboratories for routine monitoring of the activities of tAD A isoenzymes (16) .
The cytokines IL-l /3, IL-6, IL-8, TNF -a, VEGF and the chemokine MCP-l, as well as the sIL-2R were measured by enzyme-linked immunosorbent assay (ELISA) using a commercially available ELISA kit according to the protocol supplied by the manufacturer.
RESULTS
The immune system is involved and activated in the course of ABD. Given the immunological activity in ABD, pro-inflammatory cytokines, chemokines and mediators may be effected in the course of the disease (17) (18) . The present study showed that the patient had significantly elevated IL-6 levels during the active period of the disease, and in addition, even during remission the IL-6 levels were significantly higher than normal subjects but lower than during the activity. Since IL-6 is a key activator of the acute-phase response and is implicated in liver synthesis of acute-phase reactants, it is likely to play an important role in the course of ABO (19) . The results of the study indicate that acute phase reactants were higher during the acute phase and the relapse of the disease and lower during the treatment and the remission of the disease. The above parameters in patients with ABO may indicate sensitive inflammation markers which reflect the presence and activity of the disease (20) .
This study showed that IL-I~levels of ABO patient were below the detection limits of the assay in all samples, although, IL-I~systemically regulates the metabolic, immuno-inflammatory and reparative properties and can be a mediator of some diseases.
DISCUSSION
TNF-a, as IL-6, is a pro-inflammatory cytokine involved in the blood-retinal barrier breakdown by opening tight junctions of retinal vascular endothelial cells (3, (21) (22) . TNF-a levels in the serum of the patient with ABO were significantly higher in the active than in the inactive phase of ABO. It is probable that the disease activity is associated with the secretion of pro-inflammatory mediators by direct activation of circulating monocytes (3, 5) .
Also, this study showed that IL-8 levels were significantly higher in the active phase of ABO when compared with the inactive phase. Since IL-8 has potent effects on neutrophils by attraction them to the sites of lesions, (a characteristic finding of ABO), we think that IL-8 most probably participates in the course of ABO (5, 23) .
T helper (Th) cells, play an important role in regulating immune and inflammatory responses, through their ability to secrete cytokines (7) . Serum level of sIL-2R was significantly higher in the active phase than in the inactive phase of ABO. It suggests that high serum levels of sIL-2R in the active period indicate the activation of the immune system in ABO and may have a pathophysiological role in the course of the disease (24) . During the inactive period there was no significant elevation of serum sIL-2R levels over normal values.
Recently, the chemoattraction of inflammatory cells in the site of inflammation has been attributed to chemokines (7), which is thought to be essential during the course of ABO, produced by a wide variety of cell types such as lymphocytes, monocytes, neutrophils and endothelial cells. The results described in this paper, indicate that ABO causes a substantial rise in the levels of the MCP-I chemokine in the circulation.
Chemoattractants, such as chemokine MCP-I, are important in the activation process (25) . By binding to receptors on leukocytes, they initiate a conformational change in the integrin, which permits the integrin to bind to its ligand on endothelial cells, thus stimulating their extravasation (26) .
VEGF is a potent endothelium-specific cytokine. It is primarily produced by neutrophils, macrophages and vascular endothelial cells, all of which participate in the course of ABO (27) . Its synthesis is stimulated in inflammatory reactions, and VEGF itself promotes inflammatory processes by mobilising leukocytes (28) . As VEGF has a direct effect on endothelial cells and is produced by the cells participating in the pathophysiology of ABO, we found elevated plasma VEGF levels in the patient with active disease and during relapse of ABO. Many possible mechanisms or factors may be responsible for the increased plasma VEGF concentrations. VEGF requires the simultaneous presence of TNF-a to induce human microvascular endothelial cells. However, pro-inflammatory cytokines IL-I~, IL-6 and TNF-a stimulate VEGF gene expression. We demonstrated that proinflammatory cytokines, TNF-a, IL-6 and IL-8 were increased in the patient with ABO, especially in the active disease and during relapse. Therefore, these cytokines may be involved in the up-regulation of endothelial cells as well as in VEGF production.
ABO is an immunologic disease. Current hypothesis for ABO is an early infiltration of T cells into the affected regions followed by a second phase of chemotaxis of neutrophils. These local changes are accompanied by central changes in circulating lymphocytes with activation of these cells.
tAOA activity in lymphoid tissues is essential for the proliferation, maturation and function of lymphocytes, particularly for T cells (29) (30) . In accordance with the reports mentioned previously, it might be suggested that tADA activity is closely related to T cell activation, and the increase in serum tADA activity could be of importance in indicating the role of activated T lymphocytes in the pathogenesis of ABD, depending on the findings presented in this study (31) (32) .
This study shows that during the active phase of ABD the levels of tADA activity, as well as ADAI and ADA2, were higher than during the inactive period. Therefore, because of low cost and easier application, the measurement of serum tADA activity may be used as a simple biochemical test for rapid preliminary evaluation of the severity of disease. It is also clinically useful for predicting relapse before clinical findings and for following-up the disease during the treatment period in ABD patients.
In conclusion, TNF-a, IL-6, IL-8 and sIL-2R levels in the patient with active and relapsed ABD were significantly higher than those in the inactive period of the disease suggesting that these cytokines are related to the disease activity. These proinflammatory cytokines may playa role during the course of the disease and may be responsible for tissue damage and for upregulation of plasma VEGF levels. Plasma VEGF levels were higher in the patient with ABD suggesting a role of VEGF in ocular vascular events in the course of the disease.
As ocular ABD is essentially diagnosed on the basis of clinical observations, plasma VEGF levels may be used as an adjunct laboratory test for the screening of disease activity. They also, may lead to novel therapies with antibodies or other inhibitors of VEGF. Serum tADA activity can be used for the diagnosis of ABD to support clinical findings and as an index for disease activity and relapse. It can be used during the follow-up period of the patients as well as to monitor the effect ofthe treatment, iffurther studies demonstrate its sensitivity and specificity.
